Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. PHIO.NASDAQ

Phio Pharmaceuticals Corp (PHIO NASDAQ) stock market data APIs

$3.95 -0.03(-0.8%) as of July 26, 2024
Price chart is built with Anychart

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Phio Pharmaceuticals Corp Financial Data Overview

3.985
3.95
-
4.065
3.55
3.3502-29.07
1 963 K
510 K
0
-0.85
1.448
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'PHIO',
Type: 'Common Stock',
Name: 'Phio Pharmaceuticals Corp',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG0024FKD97',
ISIN: NULL,
CUSIP: NULL,
CIK: '1533040',
EmployerIdNumber: '45-3215903',
FiscalYearEnd: 'December',
IPODate: '2012-05-10',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic Primary',
IsDelisted: false,
}

Phio Pharmaceuticals Corp Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -9 186 000
  • Earnings Per Share -22.68
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Phio Pharmaceuticals Corp Earnings via APIs

  • Latest Release 2024-04-01
  • EPS/Forecast -1.3

Get Phio Pharmaceuticals Corp End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Phio Pharmaceuticals Corp latest news via APIs

Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is desig...
  • EARNINGS RELEASES AND OPERATING RESULTS
  • IMMUNOONCOLOGY
  • NASDAQ:PHIO
  • PHIO
  • PHIO PHARMACEUTICALS CORP
  • RNAI

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is desig...
  • IMMUNOONCOLOGY
  • INTASYL
  • NASDAQ:PHIO
  • PHIO
  • PHIO PHARMACEUTICALS CORP
  • PRODUCT / SERVICES ANNOUNCEMENT
  • RNAI
Do you have any questions?
support@eodhistoricaldata.com